Skip to main content

A multifaceted cancer immunotherapy based on an immune checkpoint-modulating chimeric oncolytic virus vector in combination with a dendritic cell vaccine

Project description

Multifaceted oncolytic virus-based approach for cancer immunotherapy

Although immunotherapy has recently emerged as a promising approach to treat cancer, clinical responses, especially in solid tumours, have been disappointing. Hepatocellular carcinoma (HCC) is particularly challenging due to the inherently immune-suppressive microenvironment of the liver. To address this, the EU-funded ONCO-VAX project will use oncolytic viruses (OVs) to directly lyse tumour cells, as an integral part of a multi-faceted dendritic cell vaccine approach to stimulate immune responses against HCC. To overcome potential innate antiviral immune responses, scientists will characterize changes in the tumor microenvironment in response to OV therapy, and use this information to engineer new vectors to express genes that restrict immune suppression. Additional features are expected to elicit a broad and life-long immunity against the tumour.

Host institution

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
Net EU contribution
€ 1 499 988,00
Address
Ismaninger Strasse 22
81675 Muenchen
Germany

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00

Beneficiaries (1)

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
Germany
Net EU contribution
€ 1 499 988,00
Address
Ismaninger Strasse 22
81675 Muenchen

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00